Candriam SCA
ELVN icon

Candriam SCA’s Enliven Therapeutics ELVN Stock Holding History

Candriam SCA’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$38.9M Sell
846,451
-59,223
-7% -$3.23M 0.17% 113
2026
Q2 		$45.9M Buy
905,674
+311,595
+52% +$13.2M 0.21% 103
2026
Q1 		$23.3M Buy
594,079
+141,060
+31% +$3.91M 0.12% 173
2025
Q4 		$6.98M Sell
453,019
-156,333
-26% -$3.11M 0.03% 322
2025
Q3 		$12.5M Buy
609,352
+192,702
+46% +$3.88M 0.07% 242
2025
Q2 		$8.36M Buy
+416,650
New +$7.89M 0.05% 274

Other funds holding ELVN

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Candriam SCA's ELVN Position: Q3 2026 in Review

Candriam SCA reduced its Enliven Therapeutics (ELVN) stake by 6.5% in Q3 2026, selling an estimated $3.23M and leaving 846,451 shares worth $38.9M. The position accounts for 0.17% of the portfolio, ranked #113.

Candriam SCA first reported a position in ELVN in Q2 2025 and has held it in 6 quarters since. The position peaked at $45.9M in Q2 2026. 38 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • Candriam SCA held 846,451 shares of Enliven Therapeutics worth $38.9M as of Q3 2026.
  • Candriam SCA sold 59,223 Enliven Therapeutics shares in Q3 2026, an estimated $3.23M.
  • Enliven Therapeutics made up 0.17% of Candriam SCA's portfolio in Q3 2026, its #113 holding.
  • Candriam SCA first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • Candriam SCA's Enliven Therapeutics position peaked at $45.9M in Q2 2026.
  • 38 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on Candriam SCA's 13F filing for Q3 2026, filed 3 Nov 2026.